BeiGene's application for tislelizumab accepted in China for liver cancer

• The China National Medical Products Administration has accepted BeiGene's (NASDAQ:BGNE) sNDA for anti-PD-1 antibody tislelizumab for the treatment of patients with previously treated unresectable hepatocellular carcinoma, the most common form of liver cancer.
• Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.